Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CPS1 | P31327 | 6/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.43 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17350994 | 1.00 | HSD11B1 (0.55) | HSD11B1GAASMN1; SMN2NPC1RAB9A | |
| SCHEMBL17350865 | 0.86 | KMT2A (0.52) | HSD11B1GAASMN1; SMN2RAB9ALMNA | |
| SCHEMBL10243751 | 0.86 | KMT2A (0.52) | HSD11B1GAASMN1; SMN2RAB9ALMNA | |
| SCHEMBL10243899 | 0.82 | ALDH1A1 (0.53) | HSD11B1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL17350908 | 0.82 | ALDH1A1 (0.53) | HSD11B1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL17350607 | 0.81 | ALDH1A1 (0.48) | HSD11B1SMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL10243938 | 0.81 | ALDH1A1 (0.48) | HSD11B1SMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL10244092 | 0.81 | HTR4 (0.50) | GAA | |
| SCHEMBL17350852 | 0.81 | HTR4 (0.50) | GAA | |
| SCHEMBL17350931 | 0.81 | HSD11B1 (0.56) | HSD11B1NPC1RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318403-B1 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INT (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885GAA 296/4885SMN1; SMN2 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.